Dalcetrapib, a CETP inhibitor, shows an IC50 of 9 µM against rabbit plasma CETP. In rabbits fed an atherogenic diet, it raises HDL, lowers VLDL, and reduces induced atherosclerosis. In humans, it inhibits CETP activity and boosts HDL levels, but doesn't decrease recurrent cardiovascular event risk.